New IPO - Intuitive Investments - Intuitive Investments Group, a closed-end investment company focussed on the life sciences sector, announces its intention to seek admission of the entire issued and to be issued ordinary share capital of the company to the AIM market of the London Stock Exchange, and a conditional placing of 37,500,000 new ordinary shares, at a price of 20 pence per share, to raise gross proceeds of £7.5m.

Strand Hanson is acting as nominated adviser and Turner Pope Investments (TPI) is acting as broker and sole bookrunner.
<h4>Key highlights</h4>
The net proceeds will be used:
<ul>
 	<li>to invest in fast growing and / or high potential life sciences businesses, based predominantly in the UK, wider Europe and the US, chosen from an identified pipeline of investment opportunities</li>
 	<li>investments will be focused on diagnostics and healthcare, medical devices, tools and technologies and bio-therapeutics and pharmaceuticals</li>
 	<li>to capitalise on significant opportunities in growth (Series A and B), special situations and public companies, with a focus on early and late stage venture capital.</li>
 	<li>to invest in approximately 10-12 holdings, with no single investment representing more than 15% of the company's NAV</li>
</ul>
The market capitalisation of the company is expected to be circa £7.8m on admission. IIG expects to be able to benefit from access to the board's identified pipeline of over 16 potential investment opportunities.

Admission and commencement of dealings on AIM is expected at 8.00 a.m. on 14 December 2020 under the ticker AIM:IIG

[<span style="color: #e85c4e;"><em>£7.8m is a particularly small target for a new launch. The announcement says that the costs will be kept to a minimum with no external management fee and a performance-related fee for the chairman (terms not disclosed).</em></span>]
<h4>About Intuitive Investments Group</h4>
The company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the board's experience and in particular that of the chairman, David Evans, to seek to generate capital growth over the long term for shareholders.

The investment team is comprised of the chairman, the CEO and the chairman of the Advisory Panel.

<strong>David Evans, executive chairman</strong>

David Evans has over 27 years of experience in the Life Science sector, both in private companies and as a senior director of a number of public companies. David has facilitated 12 companies' transition to being publicly traded (directly or indirectly), has overseen four successful exits and has extensive experience chairing numerous UK public companies' boards. He has been actively engaged in a number of M&amp;A transactions and has a record of high returns from personal investments in the Life Science sector.

<strong>Robert Naylor, proposed CEO (appointment effective from 19 February 2021)</strong>

Robert Naylor has 24 years' experience in capital markets; most recently at Cenkos Securities plc as head of corporate finance and corporate broking in the investment funds team. Robert has advised a number of Life Science companies.

<strong>Malcolm Gillies, non-executive director</strong>

Malcolm Gillies is a lawyer by background, having worked as a senior corporate partner for over 10 years. He has since taken numerous director roles with Life Science focussed public companies.

<strong>Cormac Kilty, non-executive director</strong>

Cormac Kilty has founded a number of Life Science and Diagnostics companies and has acted as a director of many Life Science companies.

<strong>Colin Willis, non-executive director</strong>

Colin Willis specialises in venture capital, with over 24 years of experience in the field. He has set up three venture capital companies providing substantial returns to investors.
<h4>Advisory Panel</h4>
<ul>
 	<li>Dr. Stewart White, (Advisory Panel chair) has acted as chairman and CEO of numerous Life Science companies. Stewart is a visiting professor at the University of Glasgow and has a PhD in Bioprocessing.</li>
 	<li>Julian Baines is CEO of EKF Diagnostics Holdings plc (AIM:EKF) and holds an MBE for services in the Life Science sector.</li>
 	<li>Ron Long has held a number of positions as CEO and chairman of Life Science companies and several start-up businesses.</li>
 	<li>Per Matsson has experience in senior positions in various Life Science R&amp;D departments. He is also an associate professor in Veterinary Science and holds a PhD in biology.</li>
 	<li>Alastair Smith, CEO of Avacta Group plc (AIM:AVCT), was previously a professor of Molecular Biophysics and has a PhD in Physics.</li>
</ul>


&nbsp;